They provide a paper in which they propose that c-Abl signaling contributes to modulate molecular events at the interface between oxidative stress, metabolism, and DNA damage, suggesting possible therapeutic strategies targeting c-Abl for the treatment of neurodegenerative diseases. Here, ABL1 is linked to neurodegenerative disease.